Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing



  • Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets.
  • Pipeline programs in Small Cell Lung Cancer and Microsatellite-Stable Colorectal Cancer.
  • Experienced team of individuals with expertise in surface proteomics and oncology from academia, biotech and pharma, led by CEO Roman Thomas.
  • Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.

COLOGNE, Germany and ZURICH, Jan. 16, 2024 /PRNewswire/ — DISCO Pharmaceuticals (“DISCO”), a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth today. The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing of EUR 20 million and is backed by a world leading investor syndicate, including Sofinnova Partners, which led the round, Panakes Partners, M Ventures and AbbVie Ventures.

The development of new treatment modalities in oncology is growing at an ever-increasing rate, but the lack of cancer-specific cell surface targets limits the application to a few clinically effective targets. The development of new biologics, such as antibody-drug conjugates (ADCs) and bi-specific antibodies, is on the rise; however, there are currently less than 30 molecular targets which form the basis of all antibody-based therapies. Therefore, there is a significant need to identify novel cancer-specific targets and target pairs.

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-specific therapies, with the potential to boost efficacy and reduce side effects for patients. DISCO has started to create an internal pipeline of novel anti-cancer therapeutics leveraging this knowledge.

DISCO has completed the first-ever map of the surfaceome of a cancer type, Small Cell Lung Cancer, (SCLC) and is developing proprietary antibody-based treatments for SCLC, which has historically been difficult to treat. DISCO is currently working on Microsatellite-Stable Colorectal Cancer, which is associated with a high unmet medical need and for which only a few treatment options are available. The Company’s pipeline includes further undisclosed programs.

DISCO was spun out of ETH Zürich, with founders from ETH, the University of Cologne and Stanford University, and was founded in May 2022 by Prof. Roman Thomas, Dr. Johannes Heuckmann, Prof. Bernd Wollscheid and Prof. Julien Sage. The founders have a deep understanding of surface proteomics, cancer biology and drug discovery, and a track record of value creation. Dr. Stefan Ries, who has previously held leadership positions at Roche and was a venture partner at Versant Ventures, joins DISCO as Chief Scientific Officer. The DISCO team is complemented by a world leading group of scientific advisors.

In addition to the experienced Board of Directors from the investor syndicate, Dieter Weinand will join as Chairman of the Board. Dieter Weinand was previously the CEO of Bayer Pharmaceuticals and has held leadership positions at Pfizer, BMS and Sanofi. He currently serves on the Board of Coya Therapeutics (NASDAQ: COYA), as Chairman of the Boards of Replimune (NASDAQ: REPL), Umoja, and Inspirna, and as Executive Chairman of Mnemo Therapeutics. Furthermore, Carsten Reinhardt, M.D., Ph.D., Chief Development Officer at Immatics (NASDAQ: IMTX), joins the DISCO Board as an Independent Director. Previously, he was EVP and Chief Medical Officer at Micromet Inc, International Medical Leader at Hoffmann-La Roche, and has been serving as a director on supervisory boards to a variety of biopharma companies.

Roman Thomas, Founder and Chief Executive Officer, at DISCO Pharmaceuticals, said: “Today, we are launching DISCO Pharmaceuticals and its breakthrough technology after a decade of research by our exceptional team. We believe that our surfaceome discovery technology is truly disruptive and will transform oncology treatment options and ultimately improve outcomes for patients. The surfaceome mapping in Small Cell Lung Cancer – that we completed within months – has validated our technology platform and approach, demonstrating its potential, and we look forward to applying it to different indications.”

Maina Bhaman, Partner at Sofinnova Partners, added: “DISCO is uniquely positioned to transform cancer care. The team, which brings together individuals with diverse backgrounds from academia, biotech and pharma, combined with its unique surfaceome discovery technology, enables comprehensive target information which neither standard proteomics, nor genome or transcriptome sequencing can provide.” 

Dieter Weinand, newly appointed Chairman of the DISCO Board of Directors, commented: “Expanding the possible target space in oncology has been a bottleneck in the industry for decades. I am thrilled to be working with the truly exceptional people at DISCO as I firmly believe that they will be able to overcome this hurdle by using their disruptive surfaceome discovery engine.

About DISCO Pharmaceuticals

DISCO Pharma, operating out of Cologne, Germany and Schlieren, Switzerland, employs a disruptive scalable technology to map the surfaceome of cancer cells and develop first-in-class cancer drugs. With the advent of new cell-surface, target-directed therapeutic modalities (including ADCs and bi-specific antibodies), it is critical to ramp up the discovery of meaningful targets. DISCO does so by comprehensively identifying druggable targets, as well as protein communities (i.e., different proteins that form nanoscale organizations on a cell), across the entire cancer cell surface at scale, thus uncovering crucial new information that neither genome nor transcriptome sequencing can provide. By knowing which proteins are truly present on the cell surface, and how they are associated within protein communities, DISCO can design highly specific binders, boosting expected efficacy and reducing side effects.

DISCO has a highly experienced team with a strong track record in cancer drug discovery and entrepreneurial value creation, as well as a deep understanding of surface proteomics born out of ETH in Zurich and developed further within the Company. DISCO is backed by world leading life sciences investors including Sofinnova Partners, Panakes Partners, M Ventures and AbbVie Ventures.

View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading